Literature DB >> 10727996

Androgen insensitivity.

B Gottlieb1, L Pinsky, L K Beitel, M Trifiro.   

Abstract

The androgen receptor (AR) protein regulates transcription of certain genes. Usually, this activity depends upon a central DNA-binding domain that permits the binding of androgen-AR complexes to regulatory DNA sequences near or in a target gene. The AR also has a C-terminal androgen-binding domain (ABD) and an N-terminal modulatory domain. These domains interact among themselves and with coregulatory, nonreceptor proteins to determine vector control over a gene's transcription rate. The precise roles of these proteins are active research areas. Severe X-linked androgen receptor gene (AR) mutations cause complete androgen insensitivity, mild ones impair virilization with or without infertility, and moderate ones sometimes yield a wide phenotypic spectrum among sibs. Different expressivity may reflect variability of AR-interactive proteins. The family history must identify heterozygous XX females with sparse, delayed, or asymmetric pubic/axillary hair or delayed menarche and infertile XY maternal aunts or uncles. Mutation type and density vary along the length of the AR. N-terminal polyglutamine tract expansion limits AR transactivation, causing a form of mild androgen insensitivity. Analysis of ABD mutations that do not impair androgen binding or impair it selectively will illuminate its intradomain properties. For partial androgen insensitivity and mild androgen insensitivity, pharmacotherapy with certain androgens or other steroids may overcome some dysfunction of certain mutant ARs. Experience with this approach is limited; outcomes have been generally disappointing. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10727996     DOI: 10.1002/(sici)1096-8628(19991229)89:4<210::aid-ajmg5>3.0.co;2-p

Source DB:  PubMed          Journal:  Am J Med Genet        ISSN: 0148-7299


  9 in total

Review 1.  Recent progress in histochemistry and cell biology.

Authors:  Stefan Hübner; Athina Efthymiadis
Journal:  Histochem Cell Biol       Date:  2012-02-25       Impact factor: 4.304

2.  Genetic issues in the care of the adolescent patient.

Authors:  Lea Velsher
Journal:  Paediatr Child Health       Date:  2003-01       Impact factor: 2.253

3.  A functional analysis of disease-associated mutations in the androgen receptor gene.

Authors:  Sean D Mooney; Teri E Klein; Russ B Altman; Mark A Trifiro; Bruce Gottlieb
Journal:  Nucleic Acids Res       Date:  2003-04-15       Impact factor: 16.971

4.  Evaluation of CAG repeat length of androgen receptor expressing cells in human testes showing different pictures of spermatogenic impairment.

Authors:  Daniela Fietz; Joachim Geyer; Sabine Kliesch; Jörg Gromoll; Martin Bergmann
Journal:  Histochem Cell Biol       Date:  2011-10-25       Impact factor: 4.304

5.  Allosteric conversation in the androgen receptor ligand-binding domain surfaces.

Authors:  Solène Grosdidier; Laia R Carbó; Víctor Buzón; Greg Brooke; Phuong Nguyen; John D Baxter; Charlotte Bevan; Paul Webb; Eva Estébanez-Perpiñá; Juan Fernández-Recio
Journal:  Mol Endocrinol       Date:  2012-05-31

Review 6.  The genetic basis of female reproductive disorders: etiology and clinical testing.

Authors:  Lawrence C Layman
Journal:  Mol Cell Endocrinol       Date:  2013-03-14       Impact factor: 4.102

Review 7.  Spinal and bulbar muscular atrophy: ligand-dependent pathogenesis and therapeutic perspectives.

Authors:  Masahisa Katsuno; Hiroaki Adachi; Fumiaki Tanaka; Gen Sobue
Journal:  J Mol Med (Berl)       Date:  2004-02-27       Impact factor: 4.599

8.  Characterization of nuclear import of the domain-specific androgen receptor in association with the importin alpha/beta and Ran-guanosine 5'-triphosphate systems.

Authors:  Natsuko Kaku; Ken-ichi Matsuda; Atsushi Tsujimura; Mitsuhiro Kawata
Journal:  Endocrinology       Date:  2008-04-17       Impact factor: 4.736

9.  Corepressive function of nuclear receptor coactivator 2 in androgen receptor of prostate cancer cells treated with antiandrogen.

Authors:  Keisuke Takeda; Noboru Hara; Tsutomu Nishiyama; Masayuki Tasaki; Fumio Ishizaki; Yoshihiko Tomita
Journal:  BMC Cancer       Date:  2016-05-25       Impact factor: 4.430

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.